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Objetivo: El objetivo del presente estudio fue desarrollar y optimizar la auto-nanoemulsión forma 
de dosificación sólida (SNESDF) de la Lovastatina para aumentar su solubilidad. Lovastatina (cuya 
solubilidad en agua es 0,4 x 10-3 mg / ml) se considera que es un fármaco razonable debido a su 
alto valor  de log P (4,3) y una buena solubilidad en aceites.
Materiales y Métodos: Las formulaciones fueron optimizadas por  el diseño estadístico Box-
Behnken  en el cual  las variables independientes como relación de tensioactivo: tensioactivo co-
(X1), aceite: tensioactivo co tensioactivo (X2), y% Aerosil (X3). Las formulaciones se caracterizan 
por sus variables dependientes, tales como tamaño de la gota (Y1), la transmitancia (Y3), el 
porcentaje de fármaco liberado en 5 minutos (Y3), y dentro de 15 minutos (Y4).
Resultados y Conclusiones: tamaño de la gota y el potencial zeta del lote optimizado resultó 
ser 21,89 nm y -6,4 mV, respectivamente. 44,32% y 90,78% del fármaco se encontró que se libera 
dentro de 5 min y 15 min, respectivamente. Por lo tanto, mediante la formulación en SNESDF de 
lovastatina ,  se encontró que la solubilidad mejoraba significativamente.
PALABRAS CLAVE: Diseño de Box-Behnken, lovastatina, Potencial Zeta, Diagrama de superficie 
de respuesta
ABSTRACT 
Aim: The aim of present study was to develop and optimized self-nanoemulsifying solid dosage 
form (SNESDF) of Lovastatin for enhancing its solubility.  Lovastatin (whose water solubility is 0.4 
x 10-3 mg/mL) is considered to be a reasonable drug because of its high log P value (4.3) and good 
solubility in oils. 
Materials and Methods: The formulations were optimized by Box-Behnken statistical design 
in which the independent variables like Ratio of surfactant: co-surfactant (X1), oil: surfactant co 
surfactant (X2), and % Aerosil (X3). The formulations were characterized for its dependent variables 
such as Droplet size (Y1), transmittance (Y3), percentage of drug released within 5 minutes (Y3), and 
within 15 minutes (Y4).
Results and Conclusion: Droplet size and zeta potential of the optimized batch was found to be 
21.89 nm and -6.4 mV, respectively. 44.32 % and 90.78 % of the drug was found to be released 
within 5 min and 15 min, respectively. Hence, by formulating into SNESDF, the solubility of 
Lovastatin was found to be significantly improved. 




Successful oral delivery of drug has always remained a 
challenge to the drug delivery field, since approximately 
40% of new drugs have poor water solubility, and thus 
oral delivery is frequently associated with implications 
of low bioavailability1. To overcome these bioavailability 
problems, various formulation strategies have been 
reported including the use of surfactants, cyclodextrin 
inclusion complexes, solid dispersion, nanoparticles and 
absorption enhancers. However the most appropriate 
formulation and their metabolic products are still worth to 
be further investigated.
 Self-nanoemulsifying drug delivery systems (SNEDDS) 
have attracted considerable amount of interest as 
potential drug delivery vehicles, largely due to simplicity 
of preparation, clarity and ability to be filtered and 
incorporate wide range of drugs of varying solubility2. 
These SNEDDS is o/w type emulsion, most suitable 
formulation, which is expected to increase the solubility 
by dissolving compounds with low water solubility into 
an oil phase. They can also enhance oral bioavailability by 
reducing the droplet size (<100 nm), and hence increase the 
rate of absorption due to surfactant-induced permeability 
changes3. Lovastatin (LOV) lowers cholesterol levels 
through reversible and competitive inhibition of all HMG-
CoA reducatse (3-hydroxy-3methylglutaryl-coenzyme 
A reductase), an enzyme involved in the biosynthesis of 
cholesterol. Lovastatin (water solubility is 0.4 x 10-3 mg/
mL) is considered to be a reasonable substrate because 
of its high log P valve (4.3) and good solubility in oils 
(55.10 and 83.54 mg/gm soybean oil and sunflower oil, 
respectively). Hence, the objective of this study was to 
enhance the solubility of Lovastatin by formulating self-
nanoemulsifying solid dosage form (SNESDF). 
Many statistical experimental designs have been recognized 
as useful techniques to optimize the process variables. 
Different types of screening designs, such as fractional 
factorial and Plackett- Burman screening designs have been 
used for preformulation evaluations4. Response surface 
methodology (RSM) is used when only a few significant 
factors are involved in optimization. Different types of RSM 
designs include 3-level factorial design, central composite 
design (CCD), Box Behnken design and D-optimal design5. 
A modified central composite experimental design, Box-
Behnken design, is an independent, rotatable or nearly 
rotatable quadratic design (contains no embedded factorial 
or fractional factorial design), in which the treatment 
combinations are at the midpoints of the edges of the process 
space and at the center6. Among all the RSM designs, Box-
Behnken design requires fewer runs (15 runs) in a 3-factor 
experimental design. A 3-factor, 3-level design would 
require a total of 27 unique runs without any repetitions 
and a total of 30 runs with 3 repetitions. Hence, the Box-
Behnken design was applied in present investigation to 
optimize the Lovastatin self-nanoemulsifying solid dosage 
forms (SNESDFs) with constraints on the release of drug 
within 15 min. 
MATERIALS AND METHODS
Materials
Lovastatin was received as a gift sample from the Torrent 
Pharmaceuticals Ltd. (Ahmedabad, India). Acrysol K 
140 and Aerosil 200 were received as gift samples from 
Corel Chemical Ltd (Ahmedabad, India). Capmul MCM 
and Capmul MCM C8 were kindly gifted by Abitech 
Corporation (USA). Tween and Span were purchased from 
S.D. Fine Chemicals (Mumbai, India). All other chemicals 
and solvents were of analytical regent grades.
Ternary phase diagram
Ternary phase diagram were constructed to obtain the 
appropriate components, and their concentration ranges 
that resulted in a large existence area of nanoemulsion were 
chosen. In order to optimize the concentration of oil phase, 
surfactant and co-surfactant, different batches of varied 
concentration were prepared and titrated with distilled 
water till transparency persisted. Ternary phase diagram 
was prepared by using a constant ratio of surfactant to co-
surfactant. Three ratio of surfactant (Acrysol K 140) and co-
surfactant (Capmul MCM C8) were selected. (1:1, 2:1, 3:1).
            
Preparation of Lovastatin Self-nanoemulsifying Solid 
Dosage Form (SNESDF)
Box-Behnken statistical screening design was used to 
optimize and evaluate main effects, interaction effects, 
and quadratic effects of the formulation ingredients on 
the in-vitro performance of SNESDF. A 3-factor, 3-level 
design is suitable for exploring quadratic response surfaces 
and constructing second-order polynomial models. The 
nonlinear computer-generated Design Expert (Trial 
Version 8.0.4.1 STAT-EASE, Bangalore), quadratic model 
is given as
Y = b0 + b1x1 + b2x2+ b3x3+b11x12 + b22x22+ b33x32+ b12 x1x2 + 
b13x1x3 + b23x2x3……..
Optimization of lovastatin self-nanoemulsifying solid dosage form.
Ars Pharm. 2013; 54(1): 07-15.
10
Figure 1. Ternary phase diagram of nanoemulsion (a) 
Acrysol K 140/ Capmul MCM C8 (2:1) and (b) Acrysol K 140/ 
Capmul MCM C8 (3:1).
Where Y is the measured response associated with each 
factor level combination; b0 is an intercept; b1to b33 are the 
regression coefficients; and X1, X2, and X3 are the independent 
variables7. The selected dependent and independent 
variables are shown in Table 1. The Ratio of surfactant: 
co-surfactant (X1), oil: surfactant co-surfactant (X2), and % 
Aerosil (X3) used to prepare each of the 15 formulations are 
given in Table 2. Lovastatin SNESDFs were prepared by 
varying the concentrations of Sunflower oil, Acrysol K140, 
Capmul MCM C8 and Aerosil. Predetermined amounts 
of the Lovastatin (10 mg) were dissolved in the required 
quantity of Sunflower oil in screw-capped glass vial and 
were warmed in a water bath at 37°C. Acrysol K140 and 
Capmul MCM C8 were added to the above mixture as a 
fixed ratio and stirred for 1 hr. All the formulations with 
different concentrations of surfactant, co-surfactant, oil and 
solid adsorbent were filled into capsules size 3 and stored 
at room temperature until used in subsequent studies8.
Characterization of Self-nanoemulsifying Solid Dosage 
Form 
Droplet size and Zeta potential measurements  
The mean droplet size and zeta potential of the resultant 
nanoemulsion was determined by dynamic light scattering, 
using a zetasizer HSA 3000 (Malvern Instruments Ltd., 
UK)9.
Transmittance study
Stability of the optimized SNESDF formulation with respect 
to dilution was checked by measuring transmittance at 650 
nm with a UV Spectrophotometer (UV-1800, Shimadzu)10.
In-vitro Dissolution Testing
Dissolution rates from different SNESDF were determined 
in 900 mL of 0.1 N HCl at 37 ± 0.5°C with stirrer rotation speed 
of 50 rpm using the USP dissolution test apparatus (TDT-
08L, Electrolab, Mumbai, India) employing a basket stirrer 
(method 1). A 10 ml aliquot of dissolution medium was 
withdrawn at 5, 10 and 15 min with a pipette. The samples 
were suitably diluted and assay spectrophotomaterically 
(UV-1800, Shimadzu) at 238 nm11.
RESULTS AND DISCUSSION 
Preparation of Self-nanoemulsifying Solid Dosage Form
The maximum amount drug was found to dissolve in 
sunflower oil (83.54 ±1.98 mg/gm). Therefore, this oil was 
selected for nanoemulsion formulation. The required HLB 
value to form o/w nanoemulsion should be between12-18 
and the selection of surfactant was mainly based on this. 
Co-surfactant was selected based on their capability to 
form a stable nanoemulsion with the relevant surfactant at 
a minimum concentration. Capmul MCM C8 was selected 
for Acrysol K140 containing nanoemulsion. Ternary 
phase diagram were constructed to obtain the appropriate 
components and their concentration range that can 
result in a large nanoemulsion existence area. From the 
ternary phase diagrams shown in Figure 1a and 1b, it was 
concluded that highest nanoemulsion zone was achieved 
for nanoemulsion containing Acrysol K140/Capmul MCM 
C8 at a ratio 3:1.   
Characterization of SNESDF
Droplet size and Zeta potential measurements
Droplet size for all the formulations was found < 90 nm 
regardless of the content used in formulation (Table 1). 
Lower value of the correlation coefficient (Eq. 1) clearly 
indicates that the response is independent of the factors 
studied. Once can be concluded that all these formulations 
resulted in acceptable droplet size range (< 100 nm) for 
nanoemulsions and no particular pattern was found (Table 
1).  As illustrated in Table 2, a p values of <0.05 for any factor 
in analysis of variance (ANOVA) indicated significant 
effect of the corresponding factor on the response. From 
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F1 1 1 0 40 91±0.98 44.5±1.34 89.56±2.12 -6.7
F2 1 -1 0 32 69.8±1.02 23.3±0.87 56.23±1.67 -9.5
F3 -1 1 0 30 85±2.67 37.8±2.09 82.56±0.95 -4.3
F4 -1 -1 0 45 69.45±3.21 34.23±1.23 74.78±0.56 -5.8
F5 1 0 1 31 74.23±2.56 34.55±1.89 69.89±1.09 -3.2
F6 1 0 -1 65 89.35±1.98 22.67±2.3 43.78±2.45 -7.8
F7 -1 0 1 29 78.23±2.16 39.34±2.76 75.23±1.23 -6.7
F8 -1 0 -1 32 78.56±0.87 41.76±1.56 81.23±1.45 -5.7
F9 0 1 1 26 84.56±2.35 35.23±2.32 64.34±1.67 -4.9
F10 0 1 -1 22 94.34±2.31 36.23±1.27 70.98±2.12 -6.3
F11 0 -1 1 34 76.34±2.56 29.34±2.32 53.23±1.67 -7.1
F12 0 -1 -1 89 78.89±1.45 38.34±1.27 65.34±1.34 -6.9
F13 0 0 0 20 93.23±2.13 47.34±1.56 86.23±1.54 -5.8
F14 0 0 0 21 89.99±2.24 46.31±1.67 86.23±1.54 -6.3





X1 = Surfactant: Co surfactant 1:1 2:1 3:1
X2 = Oil: Surfactant Co-surfactant 7:3 8:2 9:1
X3 = Percentage Aerosil 15% 20% 25%
Dependent Variables                                           
Y1 = Droplet Size (nm) < 100
Y2 = Transmittance near to 100
Y3 = Dissolution after 5 min 22.67                       47.34                    Maximum
Y4 = Dissolution after 15 min 53.23                       89.56 > 85
A* is Acrysol K-140: Capmul MCM C8
Table 1. Box-Behnken Design: Independent (X) and Dependent Variables (Y)*
the results of multiple regression analysis, it was found 
that the dependent variables, droplet size are strongly 
dependent on the independent variables (P> 0.05). 
Droplet Size (Y1) = 20.00 + 4.00X1 - 10.25X2 - 11.00X3 + 
6.63X1X1  + 10.13X2X2 + 12.62X3X3 + 5.75X1X2 - 7.75X1X3 + 
14.75X2X3 (R2 = 0.8416)     (1)
Zeta potential results of all the batches were found to be 
-3.2 mV to -9.5 mV. Aggregation is not expected to take 
place, due to the slightly negative charge of the droplets.
Transmittance Study
The results of transmittance showed wide variation (Table 
1). It can be inferred that these 3 factors have a profound 
effect on the transmittance. Formulations numbered 1, 3, 6, 
9, 10, 13, 14 and 15 showed percentage transmittance of >80 
%.  From the results of multiple regression analysis, it was 
found that transmittance are strongly dependent on the 
independent variables (P<0.05, Table 2). The correlation 
coefficients indicate a good fit.  Polynomial equation (Eq. 
2) can be used to draw a conclusion after considering 
the magnitude of the coefficient and the mathematical 
sign it carries (positive or negative). The positive sign of 
variables X1 and X2 indicated positive effect of surfactant: 
co-surfactant and oil: surfactant co-surfactant ratio on 
transmittance. 
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Droplet Size 
Source SS DF MS F Ratio P Value
Regression 4172.33 9 463.59 2.95 0.1229
Residual 785.00 5 157.00
Total 4957.33 14
Transmittance
Source SS DF MS F value
P 
Value
Regression 1024.30 9 113.81 17.57 0.0028
Residual 32.38 5 6.48
Total 1056.68 14
% Dissolution after 5 min
Source SS DF MS F value
P 
Value
Regression 654.03 9 72.67 2.35 0.0793
Residual 154.30 5 30.86
Total 808.33 14
% Dissolution after 15 min
Source SS DF MS F value
P 
Value
Regression 3498.75 9 388.75 24.14 0.0013
Residual 80.54 5 16.11
Total 3579.28 14
Table 2. Results of two way ANOVA for measured 
response. 
Transmittance (Y2) = 92.47 + 1.64X1 + 7.55X2 - 3.47X3 - 
8.55X1X1 - 5.11X2X2 - 3.83X3X3 + 1.41X1X2 - 3.69X1X3 - 1.80X2X3 
(R2 = 0.9694) (2)
It is clear that the ratio of oil: surfactant co-surfactant 
(X2) has a more positive effect then the surfactant: co-
surfactant (X1) ratio on transmittance, this may be due to 
the concentration of surfactant co-surfactant was decrease 
the interfacial tension between oil and water interface and 
give transparent nanoemulsion. Same finding was true for 
surfactant: co-surfactant is on the transmittance. 
In-vitro Dissolution Testing
From Table 1 it can be inferred that these three factors have 
a profound effect on the drug release profiles. Formulations 
numbered 1, 8, 13, 14 and 15 was >40% and only 
formulation 3 showed drug release of <40% drug release 
after 5 min. Lower value of the correlation coefficient (Eq. 
3) clearly indicates that the response is independent of the 
factors studied. From the results of multiple regression 
analysis, it was found that the dependent variables, 
percentage dissolution after 5 min are less dependent on 
DF is degree of freedom, SS is sum of square, MS is mean sum of square 
and F is Fischer’s ratio.
the independent variables  (P <0.05, Table 2). For finding 
best optimized batch study was further extended for drug 
release after 15 min.
D5 min(Y3) = 46.11 - 3.5X1 + 3.57X2 - 0.068X3 - 5.68X1X1 - 
5.47X2X2 - 5.85 X3X3 + 4.41 X1X2 + 3.57 X1X3 + 2.00 X2X3 (R2= 
0.8091)    (3)
Formulations numbered 1, 13, 14, and 15 showed higher 
drug release of >85% after 15 minutes of dissolution. 
However, the percentage of drug released after 15 min 
from formulations 3 and 8 was <85%. In order to obtain 
a formulation having rapid drug release of >85% within 
15 minutes, RSM optimization was used to determine the 
levels of these factors. The value of the correlation coefficient 
(Eq. 4) clearly indicates that the response is dependent of 
the factors studied. The positive value of the X2 variable 
represents positive effects of oil: Surfactant co-surfactant, 
where as variable X1 and X3 have negative effects on drug 
released after 5 min.  From the results of multiple regression 
analysis, it was found that the dependent variables, drug 
released after 15 min are dependent on the independent 
variables   (P <0.05, Table 2). The correlation coefficients 
indicate a good fit.
D15 min(Y4) = 85.58 - 2.29X1 + 7.23X2  - 4.33X3  - 7.37X1X1 - 
2.43X2X2 - 19.68 X3X3 + 6.39X1X2 + 17.03X1X3 + 1.37X2X3 
(R2=0.8501)   (4)
From the 3D plots, it is clear that the ratio of oil: surfactant 
co-surfactant (X2) has a major effect on determining 
drug release within 15 min from formulations (Figures 
2a, b, and c).  The Figure 2a shows that at a lower ratio 
of Acrysol K-140: Capmul MCM C8 (A*), the percentage 
drug released with an increase in the ratio of sunflower oil: 
A* (from 54.83 % to 82.73%). However, at a higher ratio 
of sunflower oil: A*, the percentage drug released from 
formulations decreased with an increase ratio of Acrysol 
K-140: Capmul MCM C8 (from 81.41% to 54.83%). This 
finding can be explained by the fact that co-surfactant by 
itself does not emulsify the oil, rather the co-surfactant acts 
by enhancing the emulsifying capability of surfactants. 
Hence, optimum ratio of surfactant and co-surfactant is a 
key factor in achieving an emulsion. The Figure 2b shows 
that at a low percentage of aerosil the percentage drug 
released from formulations increase with a decrease in the 
ratio of Acrysol K-140: Capmul MCM C8 (from 57.55% to 
81.10%). Figure 2a and 2b indicated that for obtaining the 
higher percentage drug released after 15 min the ratio of 
Acrysol K-140: Capmul MCM C8 (X1) should be kept high 
whereas ratio of sunflower oil: A* (X2) should be kept 
medium to high. Figure 2b and 2c suggested that the % 
aerosil (X3) was effective at low level so should be kept 
medium for further study. 
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Figure 2. Surface response plots for the effect of (a) independent variable X1 and X2 on % Dissolution after 15 min 
(b) independent variables X1 and X3 on % Dissolution after 15 min (c) independent variable X2 and X3 % Dissolution 
after 15 min 
Figure 4 is a representative contour plot, which further 
elucidates the effects of varying ratio of Acrysol K-140: 
Capmul MCM C8 (A*) and Sunflower oil: A* with a fixed 
amount of aerosil on all responses. Figure 3 illustrates that 
the emulsification of Acrysol K-140: Capmul MCM C8 
(A*) increases as the ratio of sunflower oil: A* is increased. 
Maximum transmittance and in-vitro drug released in 15 
min were found at Acrysol K-140: Capmul MCM C8 (A*) 
from 0 to 1 with lower levels of Sunflower oil: A* from -0.25 
to 1 as indicated by the yellow portion of the plot. Batch 
F1 falls in this region and therefore was selected as the 
best of the batches prepared according to the Box-Behnken 
design. Droplet size and percentage transmittance of batch 
F1 were found 40 nm and 91 ± 0.98, respectively. The in-
vitro dissolution study indicated that more than 85% of the 
drug released in 15 min, indicating the non interference 
Figure 3. Drug release pattern of Lovastatin SNESDF 
formulations
Optimization of lovastatin self-nanoemulsifying solid dosage form.
Ars Pharm. 2013; 54(1): 07-15.
14
of the surfactant, co-surfactant, oil and aerosil with drug 
release. Batch F1 was selected as best optimized batch for 
further study. 
Validation of the evolved mathematical models
To validate the evolved mathematical models, two check 
points were selected. Two batches CH1 and CH2 were 
prepared and evaluated (Table 3). As a confirmation 
process, a fresh formulation of Lovastatin SNCDF was 
prepared with Lovastatin (10 mg), Acrysol K-140: Capmul 
MCM C8 (A*) (2151 mg), Sunflower oil: A* (239 mg) and 
Aerosil (600 mg).  The optimized levels of factors yielded 
a formulation (batch OPT) with droplet size was <30%, 
transmittance was >90%, rapid drug release of >40% 
within 5 min and of >90% within 15 min. The observed 
and predicted values were in very close agreement, thus 
strengthening the predictability of the mathematical model. 
Further the optimized formulation had zeta potential of 
-6.4 mV.
Figure 4: Overlay plot in which the yellow region is 
the region where the constraints set on Particle size 
(< 19), Transmittance (> 90), % Dissolution in 5 min 
(>45) and in 15 min (> 80).
Response
Batch CH1
A= 0.4 & B= 0.6
Batch CH2
A= 0.6 & B= 0.4
Batch OPT
A= 0.2 & B= 0.8
Observed Predicted Observed Predicted Observed Predicted
Y1 20.08 21.54 24.78 23.69 21.89 20.26
Y2 93.89 94.79 90.89 92.92 94.67 95.45
Y3 43.45 45.03 46.23 43.58 44.32 45.24
Y4 89.75 88.48 84.67 85.59 90.78 90.07
Table 3. Validation of the evolved mathematical models
CONCLUSION 
Optimization of Lovastatin SNESDF using RSM, Box-
Behnken design, was performed. The ratio of independent 
variables, Sunflower oil, Acrysol K 140, Capmul MCM 
C8 and Aerosil 200 showed a significant effect on the 
transmittance and drug release characteristics of the 
formulation. The optimum ratio of these factors at 3 
levels was chosen based on the quantitative effect and the 
polynomial equations generated by RSM. The optimized 
formulation prepared by using these predicted levels of 
factors provided desired observed responses forming 
nanoemulsions with more than 94% transmittance and 
greater than 90% drug release within 15 min.
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